New WHO plan urges stronger action against fungal disease
New WHO Initiative Calls for Enhanced Measures Against Fungal Disease
New WHO plan urges stronger action - The World Health Organization (WHO) has released updated guidance aimed at helping nations tackle the increasing global impact of fungal infections and their resistance to antifungal treatments—a challenge often overlooked despite its significant health consequences.
On Tuesday, the WHO introduced a new Blueprint to bolster efforts against fungal diseases and antifungal resistance. This document outlines actionable strategies to improve prevention, detection, therapeutic approaches, and monitoring systems.
Key Findings
Fungal infections affect over 300 million people annually, leading to substantial mortality, prolonged illness, and major setbacks in health and productivity worldwide. These infections range from common conditions like athlete's foot and nail fungus to severe, life-threatening forms that disproportionately impact vulnerable populations, such as those with compromised immune systems, ICU patients, HIV-positive individuals, transplant recipients, and cancer patients.
Antifungal resistance is escalating, driven by the extensive use of antifungal drugs and their related compounds in human, veterinary, and agricultural sectors, as well as exposure to antifungal chemicals in the environment.
Despite these challenges, fungal diseases remain underrepresented in national health strategies, global health assessments, and most initiatives addressing antimicrobial resistance (AMR), universal health coverage, and the UN agency’s One Health program, which fosters collaboration across human, animal, plant, and environmental health.
Blueprint Framework
The Blueprint follows the recent approval of the updated Global Action Plan on AMR, adopted by the 79th World Health Assembly. This resistance phenomenon occurs when bacteria, viruses, fungi, and parasites evolve to evade drugs, complicating treatment.
"The updated AMR action plan acknowledged that fungal resistance is a vital component of the broader AMR crisis—one we can no longer ignore," stated Dr. Jean Pierre Nyemazi, interim head of WHO’s Antimicrobial Resistance Department.
Nyemazi emphasized that the Blueprint offers countries a clear roadmap for progress.
Building on WHO’s 2022 Fungal Priority Pathogens List, which highlighted 19 critical fungal pathogens, the Blueprint was crafted through a collaborative process involving over 150 experts from all WHO regions. These specialists included clinical mycologists, diagnostic researchers, policy advisors, and advocates for patient care.
The initiative targets gaps in knowledge, diagnostic capabilities, treatment options, surveillance systems, and workforce training, especially in low-resource areas.
Four Strategic Domains
The Blueprint organizes interventions around four interconnected domains, guiding implementation:
Domain 1 centers on public health systems, emphasizing awareness campaigns, antifungal stewardship programs, staff education, and infection control measures.
Domain 2 focuses on expanding access to reliable antifungal medications and diagnostic tools, alongside fostering research and innovation in pharmaceutical markets.
Domain 3 strengthens laboratory infrastructure and surveillance networks to support clinical care, inform health decisions, and prepare for outbreaks.
Domain 4 addresses societal and environmental influences, such as agricultural practices, ecological factors, and cross-sectoral health collaborations that shape fungal disease spread and resistance patterns.
"Fungal diseases and antifungal resistance continue to be overlooked in national plans and monitoring systems," noted Hatim Sati, a technical officer in WHO’s Antimicrobial Resistance Department. "This Blueprint offers a practical framework for countries to enhance their response."